Clorox (CLX) Given a $147.00 Price Target by BMO Capital Markets Analysts

Clorox (NYSE:CLX) has been assigned a $147.00 target price by equities research analysts at BMO Capital Markets in a research report issued to clients and investors on Monday. The brokerage presently has a “buy” rating on the stock. BMO Capital Markets’ price target suggests a potential upside of 13.87% from the company’s current price.

Other analysts have also recently issued reports about the company. Morgan Stanley reduced their price objective on Clorox from $140.00 to $133.00 and set an “equal weight” rating on the stock in a research note on Monday. Bank of America dropped their target price on Clorox from $155.00 to $140.00 and set a “neutral” rating on the stock in a report on Monday. Zacks Investment Research raised Clorox from a “hold” rating to a “buy” rating and set a $161.00 target price on the stock in a report on Wednesday, January 24th. Wells Fargo & Co reissued a “hold” rating and issued a $130.00 target price on shares of Clorox in a report on Wednesday, December 13th. Finally, Jefferies Group reissued a “hold” rating and issued a $148.00 target price on shares of Clorox in a report on Thursday, January 4th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and four have given a buy rating to the stock. Clorox has an average rating of “Hold” and an average target price of $132.26.

Shares of Clorox (NYSE CLX) traded up $2.09 during midday trading on Monday, hitting $129.09. The stock had a trading volume of 153,236 shares, compared to its average volume of 1,080,629. The firm has a market capitalization of $16,940.28, a PE ratio of 20.96, a P/E/G ratio of 3.15 and a beta of 0.31. The company has a debt-to-equity ratio of 2.35, a quick ratio of 0.86 and a current ratio of 1.22. Clorox has a twelve month low of $123.58 and a twelve month high of $150.40.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Friday, February 2nd. The company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.01. The business had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.43 billion. Clorox had a return on equity of 126.70% and a net margin of 13.21%. The company’s revenue for the quarter was up .7% compared to the same quarter last year. During the same period last year, the firm earned $1.14 earnings per share. sell-side analysts expect that Clorox will post 6.2 earnings per share for the current fiscal year.

In other Clorox news, SVP Michael R. Costello sold 10,574 shares of the firm’s stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $136.01, for a total transaction of $1,438,169.74. Following the transaction, the senior vice president now owns 34,867 shares of the company’s stock, valued at $4,742,260.67. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Matthew T. Laszlo sold 20,051 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $130.46, for a total value of $2,615,853.46. Following the transaction, the senior vice president now directly owns 10,896 shares in the company, valued at approximately $1,421,492.16. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.

Several hedge funds have recently modified their holdings of the business. Moors & Cabot Inc. grew its holdings in shares of Clorox by 1.2% during the second quarter. Moors & Cabot Inc. now owns 2,557 shares of the company’s stock worth $339,000 after purchasing an additional 30 shares during the last quarter. WFG Advisors LP grew its holdings in shares of Clorox by 7.2% during the second quarter. WFG Advisors LP now owns 1,571 shares of the company’s stock worth $209,000 after purchasing an additional 106 shares during the last quarter. Cetera Investment Advisers grew its holdings in shares of Clorox by 17.9% during the second quarter. Cetera Investment Advisers now owns 2,627 shares of the company’s stock worth $348,000 after purchasing an additional 399 shares during the last quarter. Stock Yards Bank & Trust Co. grew its holdings in shares of Clorox by 8.4% during the third quarter. Stock Yards Bank & Trust Co. now owns 5,172 shares of the company’s stock worth $683,000 after purchasing an additional 400 shares during the last quarter. Finally, Pinkerton Retirement Specialists LLC grew its holdings in shares of Clorox by 2.2% during the third quarter. Pinkerton Retirement Specialists LLC now owns 18,387 shares of the company’s stock worth $2,387,000 after purchasing an additional 401 shares during the last quarter. 73.68% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.thestockobserver.com/2018/02/05/cloroxs-clx-buy-rating-reaffirmed-at-bmo-capital-markets.html.

About Clorox

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply